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Abstract
The success of cancer immunotherapy reveals the power of host immunity on killing cancer cells and the feasibility
to unleash restraints of anti-tumor immunity. However, the immunosuppressive tumor microenvironment and low
immunogenicity of cancer cells restrict the therapeutic efficacy of cancer immunotherapies in a small fraction of
patients. Therefore deciphering the underlying mechanisms promoting the generation of an immunosuppressive
tumor microenvironment is direly needed to better harness host anti-tumor immunity. Early works revealed that
deregulated metabolic activities in cancer cells support unrestricted proliferation and survival by producing
macromolecules. Intriguingly, recent studies uncovered that metabolic switch in immune and endothelial cells
modulate cellular activities and contribute to the progression of several diseases, including cancers. Herein, we
review the progress on immunometabolic regulations on fine-tuning activities of immune cells and discuss how
metabolic communication between cancer and infiltrating immune cells contributes to cancer immune evasion.
Moreover, we would like to discuss how we might exploit this knowledge to improve current immunotherapies
and the unresolved issues in this field.
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Background
With more than 8 million cancer related deaths, cancer
is clearly a major health burden worldwide. Although
radiotherapy and chemotherapy elicit strong response
rates in the majority of cancer patients, metastatic dis-
eases are problematic to control via these conventional
interventions and cures remain scarce. A burgeoning
field in oncology and immunology is the ability to eradi-
cate cancer cells by rejuvenating the tumoricidal func-
tions of tumor-reactive immune cells, predominantly T
cells. Cancer immunotherapy provides oncologists with
a new weapon among existing cancer treatments, which
is demonstrated by the recent developments of check-
point blockade, adoptive cell transfer (ACT) and cancer
vaccines. However, the benefit of cancer immunotherapy
is currently compromised by the immunosuppressive
tumor microenvironment [1, 2]. While the importance
of the immunosuppressive tumor microenvironment on
dampening the anti-tumor immunity is appreciated, the
mechanism by which cancer cells instruct the develop-
ment of the immunosuppressive microenvironment re-
mains unclear.
Over the past two decades significant understanding
has been gained in cancer cell-immune system interac-
tions. Additionally, how the unrestricted proliferation
and survival of cancer cells is sustained via the deregula-
tion of cellular energetic pathways has been expounded
upon [3, 4]. However, whether the abnormal metabolic
activities of cancer cells influence the nutrient states of
the tumor microenvironment or the metabolic fitness of
neighboring stromal and immune cells remains elusive.
Similar to cancer cells, upon stimuli recognition lym-
phocytes engage metabolic reprogramming to drive their
activation and differentiation [5–7]. Therefore, cancer
and immune cells share similarities of utilizing nutrients
and engaging metabolic regulation to sustain prolifera-
tion and survival. This raises an intriguing possibility
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that “metabolic competition” within the tumor micro-
environment may allow cancer cells to effectively sup-
press anti-tumor immunity. In this review, we focus on
how immunometabolic regulations fine-tune the activa-
tion and anti-tumor responses of T cells and myeloid
cells. Moreover, we discuss the burgeoning idea that
metabolic communication and competition within the
tumor microenvironment may support the formation of
the immunosuppressive tumor microenvironment. Fi-
nally, we summarize unresolved issues in this filed and
discuss how these issues impact the development of can-
cer immunotherapy.
Reviews
The immunosuppressive tumor microenvironment: a
challenge for improving cancer immunotherapies
Progress on exploiting the host anti-tumor immunity
to combat established and aggressive tumors presents
promising effects, including on two of the most
deadly forms of cancer: melanomas and pancreatic
cancers. However, there are three major hurdles im-
peding the affect of host anti-tumor immunity and
cancer immunotherapy: 1) low number of tumor
antigen-specific T cells due to clonal deletion; 2) poor
activation of innate immune cells and accumulation
of tolerigenic antigen-presenting cells in the tumor
microenvironment; 3) formation of an immunosup-
pressive tumor microenvironment [8]. Cancer vaccines
and T cell-based treatment, such as adoptive cell
transfer (ACT) and chimeric-antigen receptor (CAR)
T-cells, have overcome the first hurdle and produced
remarkable results in several tumors. However, the
therapeutic efficacy of these treatments remains un-
satisfactory due to the incapability to fully cultivate
anti-tumor responses in the immunosuppressive
tumor microenvironment [9]. Of note, the Speiser’s
group demonstrated that tumor-reactive T cells, upon
migrating into tumors, lose their effector functions
and increase the expression of co-inhibitory receptors
compared to circulating cells [10]. Intriguingly, similar
findings have also been shown in murine tumor
models. Furthermore, short term in vitro culture is
able to restore both tumoricidal function and cytokine
production in those tumor infiltrating T cells [11].
Taken together, these findings suggest that the tumor
microenvironment provides local restraints that abol-
ish the anti-tumor responses of infiltrating T cells.
Further investigations uncovered two major under-
lying mechanisms that disarm anti-tumor immunity in
the tumor microenvironment; 1) the accumulation in
tumors of immunomodulatory cells, including M2-like
macrophages (MΦs), immature dendritic cells, regula-
tory T cells (Tregs), and myeloid derived suppressor
cells (MDSCs), diminishes T cell anti-tumor immune
responses through cell-cell contact and cytokine mi-
lieu [1, 2]; 2) expression of PD-1 receptor ligands
(PD-L1/PD-L2) and reduced expression of tumor anti-
gens and major histocompatibility complex (MHC) in
cancer cells [1]. These findings led to the develop-
ment of anti-CTLA-4 monoclonal antibody treatment,
Treg depletion therapy and checkpoint blockade, in-
cluding PD-1 and PD-L1/L2 inhibition [1, 12, 13].
Metabolic regulation of T cell anti-tumor responses
Metabolic reprogramming guides T cell activation and
differentiation
Upon receiving T cell receptor (TCR) and co-
stimulatory signals, T cells engage in growth, expan-
sion, and ultimately, differentiation into different cyto-
toxic, Tregs and helper T cells (Th cells; i.e., Th1,
Th2 and Th17) [14, 15]. In addition to these defined
signaling cascades, changes in metabolic activity has
been shown to intimately support T cell differenti-
ation and effector functions [5]. Naïve T cells rely on
oxidative phosphorylation (OXOPHOS) to maintain
energy demand; in contrast, activated T cells engage
aerobic glycolysis consuming massive amount of glu-
cose [16, 17]. Blocking glycolysis or eliminating glu-
cose uptake during T cell activation period diminishes
T cell activation, Th cell differentiation, as well as the
generation of effector cytokines, including IFNγ, IL-2,
and IL-17a in Th1 cells [5, 18]. Conversly, enhancing
glycolytic flux in T cells by overexpressing the glucose
transporter 1 (GLUT1) escalates inflammatory re-
sponses in mice [17]. In contrast to cytotoxic and ef-
fector Th cells, Tregs and memory CD8+ T cells rely
on OXOPHOS and fatty acid oxidation (FAO) to sup-
port their survival and differentiation. Blocking mito-
chondrial transport of long-chain fatty acids, a rate
limiting step of FAO, with carnitine palmitoyltransfer-
ase 1A (CPT1a) inhibitors in Tregs suppresses their
activity and survival [19]. Mammalian target of rapa-
mycin (mTOR) and AMP-activated protein kinase
(AMPK) are, mechanistically, the central energy-
monitoring system in cells. Disruption of mTOR and
AMPK activity is the critical signaling event that inte-
grates metabolic activity with cell activation and dif-
ferentiation in T cells. Impairment of glycolytic
activity in T cells suppresses mTOR, but boosts
AMPK activities, by altering the cellular ratio of
AMP/ATP. This leads to a failure to switch T cell
metabolism from catabolism into anabolism, affecting
amino acid uptake and de novo synthesis of amino
acids, nucleotides, and fatty acids [5, 18] (Fig. 1). Sup-
porting this, T cell specific mTOR deletion elevates
AMPK activity suppressing effector T cell differenti-
ation; but Treg generation from these T cells remains
intact. Furthermore, activating AMPK promotes Treg
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formation in both in vitro and in vitro assays [19,
20]. In addition to aerobic glycolysis, TCR signaling
initiates robust amino acid uptake and metabolism in
T cells that strengthen mTOR activity and instruct
the Th cell differentiation program [21–26]. These
findings suggest that mTOR and AMPK antagonize
each other to instruct T cell activation and
differentiation.
Metabolites serve as messengers to govern T cell effector
functions
Despite aerobic glycolysis and amino acid uptake be-
ing critical for T cell activation, expansion and differ-
entiation, T cells are able to survive in glucose-
depleted conditions using mitochondrial OXOPHOS
activity to support their energy demand [27]. How-
ever, as a trade-off for metabolic adaptation, T cells
decrease the production of effector molecules, includ-
ing as IFNγ, CD40L, and IL-2. Declined mTOR activ-
ity contributes to decreased effector functions;
however, several new studies have uncovered that
weakened generation of glycolytic metabolites also
contribute to T cell dysfunction. Production of
glyceraldehyde-3-phosphate (G3P) relieves the transla-
tional restraint of IFNγ and IL-2 imposed by
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[28]. Moreover, accumulation of phosphoenolpyruvate
in T cells suppresses ER calcium reuptake sustaining
the Ca2+-NFAT pathway, which controls effector mol-
ecule production [29]. These studies provide evidence
that glycolysis not only provide precursors of biomass
and ATP, but also allows activated T cells to sustain
effector functions through both transcriptional and
translational regulations.
Metabolic pathways govern macrophage polarization
Metabolic preference of M1- and M2-like macrophages
Macrophages (MΦs) are terminally differentiated im-
mune cells that possess high secretory, phagocytic, and
antigen-presenting abilities. These activities are tightly
controlled by a variety of immune stimuli such as cyto-
kines, ligands of toll-like receptors (TLRs) and other pat-
tern recognition receptors [30]. Resting MΦs
encountering microbial stimuli, such as lipopolysacchar-
ide (LPS) or LPS with pro-inflammatory cytokines ele-
vate their phagocytic activity and gain a pro-
inflammatory phenotype through the classical “M1-like
MΦs” polarization. In contrast, MΦs can engage an al-
ternative activation to become “M2-like”; thereby, sus-
taining tissue repair, angiogenesis, and Th2 immunity
upon IL-4 activation. Importantly, M2-like MΦs pro-
duce more anti-inflammatory cytokines and less co-
Fig. 1 The metabolic profile of activated, effector and memory T cells. CD8+ Tmem cell and Treg cell rely on FAO and OXPHOS for survival and to
support function. In addition, Tmem cells acquire glycerol by AQP9 for triglyceride synthesis and then promote Tmem cell proliferation and survival
(left panel). In right panel, activated effector T cells (Effect T cells, CD8+Teff cell and CD4
+Th cells) use aerobic glycolysis and FAS for proliferation.
In activated effector T cell, most pyruvate become lactate and minority of pyruvate enters TCA cycle. However, PPP yields both nucleotide and
NADPH for FAS. Glutaminolysis is also important for supplement of TCA cycle intermediates for biosynthesis
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stimulatory proteins to T cells as well as demonstrating
a reduced antigen-presenting ability [31]. In addition to
defining stimuli and downstream signaling pathways that
activate MΦs, recent research has revealed that MΦs
must engage the proper metabolic switch when activated
with LPS or IL-4. Specifically, TLR-induced signaling
promotes MΦs aerobic glycolysis by stabilizing hypoxia-
inducible factor 1a (HIF1α) and boosting mTOR activity.
This increases glycolytic activity, as well as the pentose
phosphate pathway (PPP) and de novo fatty acid synthe-
sis (Fig. 2) [6, 30, 32]. Inhibition of glycolysis or deletion
of GLUT1 prevents M1 polarization. This is phenotypic-
ally similar to treatment with either a mTOR inhibitor
or AMPK activator. Moreover, it is critical that M1-like
MΦs reduce mitochondrial OXOPHOS activity by sup-
pressing succinate catabolism in order to maintain their
pro-inflammatory properties [33]. In contract to M1-like
MΦs, M2-like MΦs display low glucose flux but high
rates of FAO and OXOPHOS via a PGC1β–dependent
metabolic switch [6, 34, 35]. Of note, impairment of
cholesterol efflux in MΦs results in a higher lipid con-
tent accompanying a M2-polarized phenotype [36, 37].
However, elevating lipid content with modified low-
density lipoprotein (LDL) has also been shown to pro-
mote inflammatory activity associated with the M1
phenotype [38]. The underlying mechanisms on this
discrepancy remain unclear, but these studies suggest
that through modulating nuclear receptor activities, such
as PPAR and LXR, the composition of lipid species may
influence MΦ polarization [7].
Macrophages: double-edge swords in tumor progression
and regression
The ability to use immunotherapy to exploit the host im-
munity to combat malignancy represents a breakthrough
for cancer treatment. However, the establishment of the
immunosuppressive tumor microenvironment is a
major impediment for current immunotherapies [8, 39].
One of the key processes disarming anti-tumor
immunity is the accumulation of M2-like tumor-
associated MΦs. Tumor outgrowth is facilitated by the
accumulation of M2-like MΦ via the prevention of
type I immune responses elicited by T cells, the formation
of abnormal vasculature and facilitating the dissipation
of metastatic cancer cells [2]. However, “re-educating”
M2-like MΦs to polarize into M1-like MΦs has been
shown to elicit tumor regression. This occurs via
restoring an immunosupportive microenvironment
marked by elevated phagocytic activity, stronger antigen-
presenting ability and secretion of pro-inflammatory
cytokines. While the contribution of tumor-associated
MΦs to cancer immune evasion and regression is
Fig. 2 Metabolic reprogramming in M1 and M2 macrophage. LPS-induced M1 macrophages are inflammatory and generate pro-inflammatory
cytokine by activation NF-κB and HIFα. M1-like macrophages display increased glycolysis to product lactate and decreased mitochondrial OXPHOS
activity. M1-like macrophages also induce PPP to increase generation of NADPH for ROS production and NO synthesis. In contrast, IL4-polarized
M2 macrophages activate STAT6 to induce PGC-1β and PPARδ/γ, which promote the expression of anti-inflammatory and metabolic genes. Thus,
M2-like macrophages exhibit increased high rates of FAO and mitochondrial OXPHOS activity
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established, many significant questions remain. Two major
questions are how cancer cells sustain the pro-
tumorigenic phenotypes of MΦs and whether cancer im-
munotherapy can “re-educate” tumor infiltrating myeloid
cells.
Cancer cell immune evasion is promoted via the nutrient-
specialized tumor microenvironment
Lactic acid and glucose in the tumor microenvironment
In the past decade, it has been demonstrated that in-
creasing aerobic glycolysis and other anabolic metab-
olism in cancer cells can sustain their unrestricted
proliferation by generating macromolecules for bio-
mass synthesis. Oncogenic mutations and dysfunc-
tion of tumor suppressor, such as p53, in these
cancer cells contribute to their abnormal cellular en-
ergetics [3, 39, 40]. These metabolic changes are sus-
pected to alter the nutrient composition in the
tumor microenvironment. For instance, the massive
generation of lactic acid from cancer cells has been
shown to suppress T cell cytotoxic and effector func-
tions; however the mechanism behind this remains
unclear. Furthermore, this generation of lactic acid
has also been shown to promote M2-polarization in
MΦs via monocarboxylate transporter-1(MCT1)-me-
diated lactic acid uptake [41]. Additionally, Colegio
et. al. discovered that lactic acid stabilizes HIF1α to
drive M2-polarization [42]. Of note, in contrast to
M2-polarization, several other reports have shown
that HIF1α stabilization promotes a M1-like macro-
phage polarization [33, 43, 44]. Although it is un-
clear how lactic acid acts differentially trigger
macrophage polarization via HIF1α stabilization, it
has been reported in cancer cells that lactic acid sta-
bilizes HIF1α in cells relying on OXOPHOS but not
in cells engaging aerobic glycolysis [45]. Therefore, it
is likely that the metabolic states of MΦs can coord-
inate with lactic acid uptake to determine their
polarization fate.
Warburg glycolysis allows cancer cells to consume glu-
cose and increase lactic acid production. Additionally,
two recent studies have independently demonstrated
that the tumor microenvironment is glucose-depleted
contributing to diminished T cell anti-tumor responses
[29, 46]. These two studies suggested that cancer cells
with higher glycolytic activity have a strong capacity to
evade immunosurveillance. Moreover, Ho et. al. discov-
ered that tumor-reactive T cells can be metabolically
rewired through phosphoenolpyruvate carboxykinase 1
(PCK1) overexpression. This restores the T cell anti-
tumor responses when infiltrating into the glucose-
deprived tumor microenvironment through regaining
phosphoenolpyruavte production [29]. Moreover, Chang
et. al. showed that PD-1 inhibition boosts T cell anti-
tumor responses by restoring mTOR activity and glu-
cose flux in tumor-reactive T cells. This has also been
observed in the chronic viral infection model and in
vitro assays [47–49]. Together, these studies provide
proof-of-concept evidence that metabolic competition
for nutrients in the tumor microenvironment is involved
in establishing and maintaining an immunosuppressive
tumor microenvironment. Furthermore, these demon-
strate that restoring metabolic fitness in T cells is a
promising approach to regain effective anti-tumor
responses.
The role of amino acid and fatty acid metabolism in
immunosuppressive tumors
In addition to lactic acid production and glucose metab-
olism, MDSCs, M2-like MΦs and cancer cells, also affect
the tumor microenvironment through degradation of
extracellular arginine levels via arginase 1 (Arg1) expres-
sion [42, 50]. Moreover, tryptophan metabolism in tu-
mors has recently gained attention for how it
contributes to immunosuppression. Expression of indo-
leamine 2,3-dioxygenase (IDO) in antigen presenting
cells (APCs) and cancer cells, promotes tumor progres-
sion and associates with poor responses to cancer im-
munotherapies in both clinical reports and murine
cancer models [26, 51]. IDO is a metabolic enzyme that
degrades tryptophan to kynurenine. Upregulated IDO
activity suppresses T cell proliferation by restricting tryp-
tophan to infiltrating T cells. Moreover, the generation
of kynurenine may enhance Tregs formation in tumors
as it has been shown to disarm gut and neuroinflamma-
tion in other disease models [52, 53]. Overall, these find-
ings indicate that the declined amino acid availability in
tumors can be harmful for mounting effective T cell
anti-tumor immunity.
As well as consuming nutrients, cancer cells also pro-
duce massive amounts of fatty acids via de novo fatty
acid synthesis, which correlates with more invasive can-
cer cells [54, 55]. In addition, accumulation of adipocytes
and adipocyte-like fibroblasts in tumors can contribute
to their metastasis [56]. These findings indicate that the
tumor microenvironment may be lipid-enriched. In sup-
port of this, tumor infiltrating MDSCs and dendritic
cells displayed higher lipid contents that associate with
strong immunosuppressive activity and weak antigen
presentation, respectively [57–60]. Of note, a fatty acid
enriched microenvironment may impinge effector T cell
functions and M1-polarization in MΦs while favoring
the generation of Tregs and M2-like MΦs [5, 34]. Fur-
ther investigation is critical to determine whether the
fatty acid content in tumors and de novo fatty acid syn-
thesis in cancer cells suppress T cell anti-tumor immun-
ity and macrophage activation.
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Unresolved questions and future directions: harnessing
metabolic regulation in cancer immunotherapy
Metabolic states of tumor infiltrating lymphocytes and
tumor-associated MΦs
Although metabolic pathways and their intermediates
control immune responses in T cells and MΦs, much of
our understanding has been formed based on in vitro
cultures. These cultures generally have a defined nutri-
ent composition and a fixed duration of stimulation.
However, the tumor microenvironment in vivo has mul-
tiple layers of regulation. For example, the abnormal vas-
culature and complicated composition of cell types likely
all influence the metabolic pathways and nutrients used
by tumor infiltrating lymphocytes and tumor-associated
MΦs. Therefore, in order to define which metabolic
pathways link to effective anti-tumor responses it will be
critical to determine the metabolic signature and profile
in tumor infiltrating lymphocytes and tumor-associated
MΦs, from progressed and regressed tumors. Addition-
ally, metabolic adaption allows T cells to engage OXO-
PHOS metabolism facilitating their survival. This
process requires the electron transport chain and func-
tional mitochondria in T cells. However, it remains un-
clear if tumor infiltrating lymphocytes are capable of
maintaining their mitochondrial fitness in order to adapt
to the glucose-depleted tumor microenvironment. Thus,
it will be important to examine the mitochondrial health
of tumor infiltrating lymphocytes.
Metabolic competition has clearly been shown to con-
tribute to the formation of the immunosuppressive
tumor microenvironment. Therefore, it will be vital for
cancer immunotherapies to develop new strategies to
allow immune cells to acquire sufficient nutrients or me-
tabolites to preserve their anti-tumor responses. Thus,
examining how to combine cancer immunotherapies
with metabolic inhibitors in order to sustain the meta-
bolic fitness of tumor-reactive T cells and M1-like MΦs
will be crucial. In addition, it will also be necessary to
elucidate if the therapeutic efficacy of cancer immuno-
therapies is associated with, as yet undefined, metabolic
features in tumors. A better understanding of how im-
munotherapies respond to different metabolic features
in tumors will further improve how we apply cancer im-
munotherapies in patients.
Why does hypoxia in tumors not improve anti-tumor
responses?
Hypoxia is a general feature of established tumors and
contributes to elevated aerobic glycolysis by stabilizing
HIF1α. Interestingly, overexpressing a degradation-
resistant mutant of HIF1α or abolishing the HIF1α-
degrading machinery promotes anti-tumor responses in
T cells, including cytotoxic activity and production of
IFNγ [61]. However, tumor infiltrating T cells fail to
maintain anti-tumor responses in tumors where hypoxia
is a general environmental stress. This raises an interest-
ing question: why does hypoxia fail to boost T cell anti-
tumor responses in tumors. The degree of HIF1α
stabilization in cancer cells is associated with the meta-
bolic pathways [45]. Therefore, we postulate that hyp-
oxia fails to stabilize HIF1α in tumor infiltrating T cells
due to their higher OXOPHOS metabolism, triggered by
PD1 signaling, and the nutrient composition in the
tumor microenvironment. If this is true, PD1 inhibition
will restore hypoxia-induced HIF1α stabilization, thereby
enhancing tumoricidal activity of tumor infiltrating T
cells. Another possibility is that hypoxia truly boosts
glycolytic rates in tumor-infiltrating T cells by stabilizing
HIF1α; however, the available glucose in the tumor
microenvironment is insufficient to support T cell anti-
tumor responses. More extensive studies are needed to
resolve this and will offer an immediate impact on the
development of new combined treatments.
How can we improve the metabolic fitness of T cells in ACT
therapy?
Reduced expression of tumor antigens and the MHCI
complex in cancer cells provides a growth advantage for
aggressive tumors by evading T cell mediated immune
destruction. The invention of CAR T-cells gives the abil-
ity to re-direct the targeting specificity to cancer cells,
thereby enhancing the anti-tumor responses in ACT im-
munotherapy [62]. However, the therapeutic outcome of
CAR T-cells on treating solid tumors is disappointing.
Interestingly, combining CAR T-cells with PD-1 block-
ade drastically improves anti-tumor responses, suggest-
ing that restrictions due to the tumor microenvironment
limit the CAR T cell induced anti-tumor immunity [63].
Engaging aerobic glycolysis and amino acid metabolism
is a prerequisite for proper T cell activation upon TCR
stimulation. However, the intracellular signaling path-
ways and metabolic requirement for sustaining CAR T-
cell activation and anti-tumor responses are not fully
understood. Given that metabolic competition between
cancer cells and infiltrating T cells leads to T cell anergy
and dysfunction, it will be important to investigate
whether CAR signaling also relies on the metabolic
switch to sustain anti-tumor responses. If it is true, it
may be possible to improve the metabolic fitness and
flexibility of CAR T cells with genetic and chemical
approaches.
In addition to CAR T-cells, memory tumor-reactive T
cells have been shown to elicit superior anti-tumor re-
sponses than effector T cells do [64]. During in vitro as-
says secondary effector T cells generated from memory
T cells, display stronger aerobic glycolysis and IFNγ pro-
duction than primary effector T cells [65, 66]. Therefore,
these secondary effector T cells can plausibly acquire
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sufficient glucose when in the tumor microenvironment
even under “metabolic competition” with cancer cells.
Moreover, memory T cells also possess healthier mito-
chondria, which may help adaptation to a nutrient crisis
more effectively [65]. Accordingly, it will be important
to gain a detailed understanding of the underlying mech-
anisms contributing to the stronger metabolic fitness
seen in secondary effector T cells. This knowledge will
feasibly provide a blueprint for manipulating transferred
tumor-reactive T cells. Ultimately, this may allow tumor-
reactive T cells to be conferred with enhanced metabolic
fitness and effector functions specifically in the nutrient-
specialized tumor microenvironment.
Conclusions
Cancer immunotherapy provides an exciting oppor-
tunity to introduce a powerful weapon to the arsenal
of cancer treatment. However, it is crucial to under-
stand how the intensive communication in the tumor
microenvironment efficiently diminishes anti-tumor
immunity. Modulation of cellular metabolism has
been shown to play a cardinal role in controlling im-
mune responses in a variety of immune cells. Despite
this, deregulated cancer metabolism represents a
newly appreciated hallmark for cancer cells. Further
research in this field will be vital to provide the foun-
dation for new treatments that target cancer metabol-
ism. Here, we hypothesize that changing the
immunostimulatory and immunosuppressive nutrients
and metabolites within the tumor microenvironment
denotes a new immunomodulatory mechanism in tu-
mors (Fig. 3). Altering the nutrient composition al-
lows cancer cells to evade from immunosurveillance
and, even coax the formation and accumulation of
pro-tumorigenic immune cells. A clear understanding
of how the immunometabolic regulation controls im-
mune responses, as well as identifying immunostimu-
latory and immunosuppressive nutrients, will allow
immune responses in tumors to be rebalanced with
genetic and/or nutritional approaches.
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